Evidence map›Paper›PMID 33326447›Full record

ArticlePloS one2020

Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence.

Haley C Dahl, Mohammed Kanchwala, Shayna E Thomas-Jardin, Amrit Sandhu, Preethi Kanumuri, Afshan F Nawas, Chao Xing, Chenchu Lin, Daniel E Frigo, Nikki A Delk

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. KInternational journal of molecular sciences · 2021
    Article
  12. Review
  13. Chronic IL-1 Exposed ARJournal of cellular signaling · 2021
    Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Haley C DahlBiological Sciences Department, The University of Texas at Dallas, Richardson, TX, United States of America.
Mohammed KanchwalaMcDermott Center of Human Growth and Development, The University of Texas Southwestern Medical Center, Dallas, TX, United States of America.
Shayna E Thomas-JardinBiological Sciences Department, The University of Texas at Dallas, Richardson, TX, United States of America.
Amrit SandhuBiological Sciences Department, The University of Texas at Dallas, Richardson, TX, United States of America.
Preethi KanumuriBiological Sciences Department, The University of Texas at Dallas, Richardson, TX, United States of America.
Afshan F NawasBiological Sciences Department, The University of Texas at Dallas, Richardson, TX, United States of America.ORCID 0000-0001-5606-9603
Chao XingMcDermott Center of Human Growth and Development, The University of Texas Southwestern Medical Center, Dallas, TX, United States of America.
Chenchu LinDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Daniel E FrigoDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.ORCID 0000-0002-0713-471X
Nikki A DelkBiological Sciences Department, The University of Texas at Dallas, Richardson, TX, United States of America.ORCID 0000-0001-9482-3830
The University of Texas at Dallas · USThe University of Texas Southwestern Medical Center · USHouston Methodist · USThe University of Texas MD Anderson Cancer Center · US

Funding

UT Southwestern Center for Translational Medicine (UL1/KL2/TL1)UL1TR001105 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$24.5M
Targeting Tumor Microenvironment-Induced Therapy Resistance in Prostate Cancer Bone MetastasisP50CA140388 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI THOMPSON, TIMOTHY CHARLES · 2009 to 2022
$23.4M
Genetic & Metabolic Dissection of the CaMKKbeta Signaling Axis in Prostate CancerR01CA184208 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FRIGO, DANIEL EDWARD · 2015 to 2019
$1.9M
NCATS NIH HHS UL1 TR001105NCI NIH HHS P50 CA140388NCI NIH HHS R01 CA184208
6 · The paper itself

Abstract

Chronic inflammation promotes prostate cancer (PCa) initiation and progression. We previously reported that acute intereluekin-1 (IL-1) exposure represses androgen receptor (AR) accumulation and activity, providing a possible mechanism for IL-1-mediated development of androgen- and AR-independent PCa. Given that acute inflammation is quickly resolved, and chronic inflammation is, instead, co-opted by cancer cells to promote tumorigenicity, we set out to determine if chronic IL-1 exposure leads to similar repression of AR and AR activity observed for acute IL-1 exposure and to determine if chronic IL-1 exposure selects for androgen- and AR-independent PCa cells. We generated isogenic sublines from LNCaP cells chronically exposed to IL-1α or IL-1β. Cells were treated with IL-1α, IL-1β, TNFα or HS-5 bone marrow stromal cells conditioned medium to assess cell viability in the presence of cytotoxic inflammatory cytokines. Cell viability was also assessed following serum starvation, AR siRNA silencing and enzalutamide treatment. Finally, RNA sequencing was performed for the IL-1 sublines. MTT, RT-qPCR and western blot analysis show that the sublines evolved resistance to inflammation-induced cytotoxicity and intracellular signaling and evolved reduced sensitivity to siRNA-mediated loss of AR, serum deprivation and enzalutamide. Differential gene expression reveals that canonical AR signaling is aberrant in the IL-1 sublines, where the cells show constitutive PSA repression and basally high KLK2 and NKX3.1 mRNA levels and bioinformatics analysis predicts that pro-survival and pro-tumorigenic pathways are activated in the sublines. Our data provide evidence that chronic IL-1 exposure promotes PCa cell androgen and AR independence and, thus, supports CRPCa development.

Indexed as

AndrogensBenzamidesCell Line, TumorCell SurvivalDrug SynergismHumansInterleukin-1Intracellular SpaceMaleNF-kappa B p50 SubunitNitrilesPhenylthiohydantoinProstatic NeoplasmsReceptors, AndrogenSignal TransductionTime FactorsAndrogensBenzamidesenzalutamideInterleukin-1NF-kappa B p50 SubunitNitrilesPhenylthiohydantoinReceptors, AndrogenTumor Necrosis Factor-alpha

Identifiers

PMID33326447
PMCPMC7743957
OpenAlexW3112702786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.